Becker's Healthcare March 8, 2024
Wegovy, Novo Nordisk’s weight loss therapy part of a popular drug class, is now approved for reducing the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are either obese or overweight, the FDA said March 8.
The injectable medication is the first glucagon-like peptide-1 receptor agonist — a drug class that includes Ozempic, Mounjaro and Trulicity — to be approved for serious heart problems in obese and overweight adults.
The FDA’s approval label hooks on that Wegovy (semaglutide) should be used...
Today's Sponsors
Today's Sponsor